OTC: ZEOX · Life Sciences · 6 alerts · CIK 1557376
Share price
$0.7960Close, Nov 13
Market cap
$6.24M
Shares outstanding
7.84MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Zeo ScientifiX, Inc. filings on SEC EDGAR ↗
Zeo ScientifiX announced that its manufacturing facility is the first to achieve Quality Management Systems (QMS) Certification under a newly established program by the Association for the Advancement of Blood & Biotherapies (AABB). This certification serves as an independent validation of the company's manufacturing quality and operational discipline in the regenerative medicine sector.
Counterparty
Association for the Advancement of Blood & Biotherapies
Zeo ScientifiX entered into a definitive strategic agreement with Pluri Inc. to expand U.S. manufacturing and commercialization of regenerative medicine products. As part of the license-for-equity transaction, Pluri will grant ZEO an exclusive license to its proprietary 3D cell expansion platform in exchange for a 41% equity stake in ZEO and a share swap involving 4% of each company's outstanding stock.
Zeo ScientifiX and Pluri Inc. entered into a definitive strategic agreement to expand their U.S. manufacturing and commercialization platform for regenerative medicine and aesthetics. The transaction involves a share exchange that will result in Pluri owning 50% of ZEO, combining Pluri's 3D cell-expansion technology with ZEO's biologics manufacturing and physician sales network.
Zeo ScientifiX, Inc. reported a working capital deficit of $1,915,000 as of October 31, 2025, which improved to a positive $65,000 by June 30, 2026. The company remains dependent on external investment capital to fund operations and faces significant risks regarding supply chain stability and its ability to continue as a going concern.